Lakefront Biotherapeutics
LKFT
Lakefront Biotherapeutics (LKFT) analyst forecast and price target
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| RBC Capital | Maintained | Sector Perform | $26.00 from $28.00 | Aug 11, 2026 |
| Morgan Stanley | Maintained | Equal-Weight | $26.00 from $30.00 | Aug 11, 2026 |
| RBC Capital | Maintained | Sector Perform | $33.00 from $32.00 | Feb 25, 2026 |
| RBC Capital | Maintained | Sector Perform | $32.00 from $28.00 | Nov 7, 2025 |
| RBC Capital | Maintained | Sector Perform | $28.00 from $27.00 | Oct 22, 2025 |
| Leerink Partners | Upgraded | Market Perform → Outperform | $40.00 from $29.00 | Oct 21, 2025 |
| Morgan Stanley | Downgraded | Equal-Weight → Underweight | $22.00 from $31.00 | Feb 14, 2025 |
| Barclays | Downgraded | Equal-Weight → Underweight | — | Jan 23, 2025 |
| RBC Capital | Maintained | Sector Perform | $30.00 from $32.00 | Nov 1, 2024 |
| Leerink Partners | Initiated Coverage | Market Perform | $24.00 | Sep 9, 2024 |
| Morgan Stanley | Maintained | Equal-Weight | $38.00 | Apr 22, 2024 |
| B of A Securities | Downgraded | Neutral → Underperform | $31.00 from $41.00 | Apr 1, 2024 |
| B of A Securities | Downgraded | Neutral → Underperform | $31.00 from $41.00 | Mar 28, 2024 |
| Morgan Stanley | Initiated Coverage | Equal-Weight | $38.00 | Mar 7, 2024 |
| B of A Securities | Maintained | Neutral | $44.00 from $41.00 | Jan 2, 2024 |
| Morgan Stanley | Maintained | Equal-Weight | $40.00 from $42.00 | Aug 7, 2023 |
| Morgan Stanley | Maintained | Equal-Weight | $42.00 | Aug 1, 2023 |
| Morgan Stanley | Maintained | Equal-Weight | $42.00 | Jul 31, 2023 |
| Morgan Stanley | Maintained | Equal-Weight | $42.00 | Jul 24, 2023 |
| Morgan Stanley | Maintained | Equal-Weight | $42.00 | Jul 17, 2023 |
Frequently asked questions
What is the latest analyst rating on LKFT?
On Aug 11, 2026, RBC Capital maintained Lakefront Biotherapeutics at Sector Perform with a price target of $26.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.